Appendix 4C - Quarterly report
31 January 2017 Enclosed is the quarterly report for the period ending...
Read More
CLINUVEL Newsletter - December 2016
20 December 2016 At the end of a calendar year we look...
Read More
Results of Meeting
28 November 2016 In accordance with Listing Rule 3.13.2 and section 251AA...
Read More
Chair's Address to the Annual General Meeting
27 November 2017 I would like to commence my address by saying...
Read More
Managing Director's AGM Presentation
27 November 2016 Good morning and welcome to CLINUVEL’s Annual General Meeting....
Read More
CLINUVEL agrees with FDA on New Drug Application timelines
8 November 2016 CLINUVEL today announced that it met on 7 November with...
Read More
Response to Price Query
31 October 2016 Enclosed is CLINUVEL PHARMACEUTICALS LTD’s response to a price...
Read More
Notice of Annual General Meeting/Proxy Form
26 October 2016 This Explanatory Memorandum has been prepared for the Shareholders...
Read More
Appendix 4G
26 October 2016 Enclosed is the Corporate Governance Council Principles and Recommendations...
Read More
CLINUVEL relocates Melbourne office
24 October 2016 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL...
Read More
FDA erythropoietic protoporphyria (EPP) scientific workshop
24 October 2016 The US Food and Drug Administration (FDA) will today...
Read More
SCENESSE® NICE ENGLAND UPDATE
18 October 2016 CLINUVEL [ASX: CUV; Nasdaq International Designation ADR: CLVLY; Xetra-DAX: UR9] today...
Read More